First Name
|
Last Name
|
Country
|
Title
|
| Johannes |
Attems |
UK |
THE NEUROPATHOLOGICAL DIAGNOSIS OF LEWY BODY DISEASES; AN UPDATE |
| Randall |
Bateman |
USA |
THE RELATIONSHIPS BETWEEN AMYLOID, TAU, AND NEURODEGENERATION IN ALZHEIMER’S DISEASE PATHOPHYSIOLOGY AND BIOMARKERS |
| Kaj |
Blennow |
Sweden |
UPDATE ON AMYLOID, TAU, NEURODEGENERATION AND GLIAL (ATNG) BLOOD BIOMARKERS FOR ALZHEIMER’S DISEASE |
| Mathew |
Blurton Jones |
USA |
USING HUMAN IPSC-MICROGLIA AND CHIMERIC MICE TO STUDY THE GENETICS OF ALZHEIMER’S DISEASE |
| Guojun |
Bu |
USA |
APOE AND LIPID METABOLISM: IMPACT ON BRAIN AGING AND ALZHEIMER’S DISEASE |
| Luc |
Buee |
France |
NANOBODIES TARGETING THE CORE OF TAU FILAMENTS |
| Frédéric |
Checler |
France |
EXOPEPTIDASES INVOLVED IN AB N-TERMINAL TRUNCATION: IDENTIFICATION, CONTRIBUTION TO AD NEUROPATHOLOGY AND BEHAVIORAL DEFECTS AND ALTERATIONS IN AD BRAINS |
| Don |
Cleveland |
USA |
THERAPEUTICALLY VIABLE GENERATION OF HIPPOCAMPAL NEURONS WITH ANTISENSE OLIGONUCLEOTIDE SUPPRESSION OF PTB |
| Claudio A. |
Cuello |
Canada |
NGF METABOLISM, ALZHEIMER’S PATHOLOGY AND PRECLINICAL BIOMARKERS |
| Jeffrey |
Cummings |
USA |
THE ALZHEIMER’S DISEASE DRUG DEVELOPMENT PIPELINE: UPDATE AND NEW DIRECTIONS |
| Bart |
De Strooper |
Belgium |
SPATIAL TRANSCRIPTOMICS TO ANALYZE THE PATHOLOGICAL CELLULAR NICHES IN ALZHEIMER’S DISEASE |
| Marc |
Diamond |
USA |
FUNCTIONAL GENETIC CLASSIFICATION OF ASSEMBLY STRUCTURES IN TAUOPATHIES |
| Rachelle |
Doody |
USA |
TACKLING NEURODEGENERATIVE DISEASES: USING SYNERGIES ACROSS DISEASE AREAS TO SPEED DRUG DEVELOPMENT FOR PATIENTS |
|
|
|
|
| Maria Teresa |
Ferretti |
Switzerland |
SEX AND GENDER CONSIDERATIONS IN NEURODEGENERATIVE DISEASES: SCIENTIFIC EVIDENCE, BIASES, AND OPPORTUNITIES FOR PRECISION MEDICINE |
| Adam |
Fleisher |
USA |
ADVANCEMENTS IN AD DRUG DEVELOPMENT – EVOLVING USE OF BIOMARKERS AND CLINICAL TRIAL DESIGN. |
| Nick |
Fox |
United Kingdom |
BIOMARKER PREDICTION OF CLINICAL ONSET: INSIGHTS FROM FAMILIAL ALZHEIMER’S DISEASE |
| Dan |
Frenkel |
Israel |
METABOLIC CHANGES IN MICROGLIA AND THEIR EFFECT ON NEUROTOXICITY IN PARKINSON’S DISEASE |
| Giovanni |
Frisoni |
SWITZERLAND |
THE PROBABILISTIC AMYLOID CASCADE HYPOTHESIS OF ALZHEIMER’S DISEASE |
| James |
Galvin |
USA |
THE HEALTHY BRAIN INITIATIVE: EXAMINATION OF RESILIENCE AND VULNERABILITY FACTORS TO DISTINGUISH HEALTHY BRAIN AGING FROM NEURODEGENERATIVE DISEASE |
| Klaus |
Gerwert |
Germany |
ABETA-STRUCTURE PREDICTS CLINICAL ALZHEIMER’S 17 YEARS BEFORE CLINICAL CONVERSION |
| Michel |
Goedert |
UK |
CRYO-EM STRUCTURES OF AMYLOID FILAMENTS FROM HUMAN BRAIN |
| Gabriel |
Gold |
Switzerland |
DO VASCULAR RISK SCORES PREDICT CEREBRAL VASCULAR LESIONS? |
| Todd |
Golde |
USA |
THE AMYLOID Β PROTEIN ASSOCIATED PROTEOME YIELDS NEW TARGETS FOR ALZHEIMER’S DISEASE THERAPEUTICS |
| Steven |
Gomperts |
USA |
CARBON MONOXIDE AT LOW DOSES REDUCES DOPAMINE CELL LOSS AND ALPHA-SYNUCLEIN PATHOLOGY IN MODELS OF PARKINSON’S DISEASE |
| John |
Growdon |
USA |
DEMENTIA COMES TO PARKINSON DISEASE: MOLECULAR BASES AND HOW TO DETECT THEM |
| Christian |
Haass |
Germany |
THERAPEUTIC TARGETING OF MICROGLIAL FUNCTIONS |
| Harald |
Hampel |
USA |
AMYLOID-Β PATHWAY ACROSS TIME AND SPACE IN ALZHEIMER’S DISEASE |
| Michael |
Heneka |
Germany |
CELLULAR INTERACTIONS OF MICROGLIA IN NEURODEGENERATIVE DISEASE |
| Joachim |
Herz |
USA |
PREVENTION OF ALZHEIMER’S DISEASE BY RESTORING ENDOSOMAL TRAFFICKING |
| David |
Holtzman |
USA |
AMYLOID-INDUCED TAU SEEDING/SPREADING: ROLE OF MICROGLIA, TREM2, AND APOE |
| Costantino |
Iadecola |
USA |
TAU MICROANGIOPATHY: FROM NETWORK DYSFUNCTION TO DISORDERED NEUROVASCULAR COUPLING |
| Takeshi |
Iwatsubo |
Japan |
ESTABLISHING TRIAL READY COHORT OF PRECLINICAL ALZHEIMER’S DISEASE IN JAPAN |
| Clifford |
Jack |
USA |
OPPORTUNITIES TO UPDATE THE NIA AA RESEARCH FRAMEWORK IN THE PLASMA BIOMARKER ERA |
| William |
Jagust |
USA |
TAU IN THE TEMPORAL LOBE: NEURAL ACTIVITY, MEMORY, AND AGING |
| Jung-Hwan |
Shin |
Korea |
VIDEO-BASED GAIT ANALYSIS |
| Keith |
Johnson |
USA |
TAU BIOMARKERS: UPDATE ON CLINICAL TRIAL DESIGNS, AND APPROPRIATE USE |
| Miia |
Kivipelto |
Sweden |
WORLD-WIDE FINGERS UPDATES: TOWARDS PERSONALIZED DEMENTIA PREVENTION AND GLOBAL STRATEGIES |
| Amos |
Korczyn |
Israel |
IS ALPHA-SYNUCLEIN A POTENTIALLY USEFUL THERAPEUTIC TARGET IN PD? |
| Frank |
Laferla |
USA |
MODELING LATE-ONSET ALZHEIMER’S DISEASE IN MICE |
|
|
|
|
| Seung-Jae |
Lee |
Korea |
INTERPLAY BETWEEN NEUROINFLAMMATION AND AGGREGATE PROPAGATION |
|
|
|
|
|
|
|
|
| Ken |
Marek |
USA |
STRATEGIES TO DEVELOP PRODROMAL BIOMARKER SIGNATURES IN PARKINSON DISEASE |
| Eliezer |
Masliah |
USA |
NOVEL IMMUNE SYSTEM THERAPEUTICAL TARGETS FOR SYNUCLEINOPATHIES OF THE AGING POPULATION |
| Pamela |
McLean |
USA |
THERAPEUTIC STRATEGIES FOR SYNUCLEINOPATHIES |
| Daniel M. |
Michaelson |
Israel |
APOE4: AN EMERGING THERAPEUTIC TARGET FOR ALZHEIMER’S DISEASE |
| Asuka |
Morizane |
Japan |
CELL REPLACEMENT THERAPY FOR PARKINSON’S DISEASE WITH IPS CELLS |
| John |
Morris |
USA |
DIAGNOSTIC ACCURACY OF THE ADNI CLINICAL DIAGNOSIS OF ALZHEIMER DISEASE: A CLINICOPATHOLOGICAL STUDY |
| Henrietta |
Nielsen |
Sweden |
APOE BEYOND THE BRAIN |
| Agneta |
Nordberg |
Sweden |
TRANSLARTIONAL IMAGING STUDIES OF REACTIVE OF REACTIVE ASTROCYTES AT DIFFERENT STAGES OF AD- IMPLICATION FOR EARLY DIAGNOSIS AND TREATMENT |
| Chiba-Falek |
Ornit |
USA |
GENE THERAPY APPROACHES TARGETING SNCA EXPRESSION FOR PRECISION MEDICINE IN PARKINSON’S DISEASE AND RELATED DISORDERS |
| Tiago |
Outerio |
Germany |
EPIGENETIC AND EPITRANSCRIPTOMIC REGULATION OF GENE EXPRESSION IN MODELS OF PARKINSON’S DISEASE |
| Ronald |
Petersen |
USA |
CLINICAL AND BIOMARKER COMBINATIONS FOR EARLY ALZHEIMER’S DISEASE TRIALS |
| Marco |
Prado |
Canada |
CHANGES IN VESICULAR ACETYLCHOLINE TRANSPORTER (VACHT) LEVELS HAVE A CAUSAL EFFECT ON AMYLOID PATHOLOGY, COGNITIVE FUNCTION AND NEURODEGENERATION |
| Gill |
Rabinovici |
USA |
MECHANISMS UNDERLYING HETEROGENEITY IN ALZHEIMER’S DISEASE: INSIGHTS FROM PET |
| Laura |
Ranum |
USA |
EXPANDING ROLE OF MICROSATELLITE REPEATS IN NEURODEGENERATIVE DISEASE |
| Stephen |
Salloway |
USA |
CREATING PATHWAYS FOR BREAKTHROUGHS IN ALZHEIMER’S DISEASE |
| Philip |
Scheltens |
The Netherlands |
THE LONG JOURNEY OF DRUG DEVELOPMENT IN AD: HURDLES, PITFALLS AND LESSONS LEARNED |
| Michael |
Schlossmacher |
Canada |
APPLYING DR. HORNYKIEWICZ’S LEGACY: STUDYING THE HUMAN BRAIN WILL REVEAL SECRETS (AND VARIANTS) OF PARKINSON’S |
| Reinhold |
Schmidt |
Austria |
ADVANCED MR SEQUENCES FOR DETECTING STRUCTURAL ABNORMALITIES IN BRAIN AGING AND DEMENTIA |
| Taylor |
Schmitz |
Canada |
CORTICAL MAPPING OF TAU AGGREGATION AND CHOLINERGIC DENERVATION WITH MULTIMODAL POSITRON EMISSION TOMOGRAPHY |
| Lon |
Schneider |
USA |
DOMINANTLY INHERITED ALZHEIMER’S NETWORK TRIALS UNIT (DIAN-TU) TAU NEXGEN PLATFORM TRIAL OF THE ANTI-TAU ANTIBODY, E2814, WITH BACKGROUND LECANEMAB THERAPY |
| Menahem |
Segal |
Israel |
PRESENILINS, OXIDATIVE STRESS AND CELL DEATH IN ANIMAL MODELS OF AD |
| Tamara |
Shiner |
Israel |
DEMENTIA WITH LEWY BODIES: IMPACT OF GBA MUTATIONS AND OTHER COMMON GENETIC FACTORS |
| Sam |
Sisodia |
USA |
IMPACT OF THE GUT MICROBIOME ON AMYLOIDOSIS AND MICROGLIAL FUNCTION |
| Beka |
Solomon |
Israel |
INHIBITION OF CXCR4/CXCL12 SIGNALING: A TRANSLATIONAL PERSPECTIVE FOR ALZHEIMER’S DISEASE TREATMENT |
| Reisa |
Sperling |
USA |
HOW EARLY DO WE NEED TO INTERVENE TO ACTUALLY PREVENT ALZHEIMER’S DEMENTIA? |
| Maria Grazia |
Spillantini |
UK |
INTERACTION BETWEEN NEURONES AND GLIAL CELLS IN NEURODEGENERATIVE DISEASES WITH PROTEIN AGGREGATION |
| Peter |
St. George-Hyslop |
Canada |
NORMAL AND PATHOLOGICAL MICROGLIAL SIGNALLING PATHWAYS |
| Fabrizio |
Stocchi |
Italy |
TREATMENT OF PARKINSON’S DISEASE: WHAT ABOUT THE NEXT FUTURE |
| Tom |
Sudhof |
USA |
REGULATION OF SYNAPTIC FUNCTION BY ALZHEIMER’S DISEASE ASSOCIATED GENES |
| Rudy |
Tanzi |
USA |
ALZHEIMER’S DISEASE IS A GENETICALLY HETEROGENEOUS INNATE IMMUNE DISORDER |
|
|
|
|
| Christine |
Van Broeckhoven |
Belgium |
GENETIC COMPLEXITY AND RARE VARIANTS IN NEURODEGENERATIVE BRAIN DISEASES |
| Robert |
Vassar |
USA |
THE CASE FOR LOW-LEVEL BACE1 INHIBITION FOR THE PREVENTION OF ALZHEIMER DISEASE |
| Carina |
Wattmo |
SWEDEN |
INTERACTION EFFECT OF SEX AND ONSET OF ALZHEIMER’S DISEASE—RATES OF PROGRESSION AND PROGNOSIS |
| Michael |
Weiner |
USA |
IMPROVING GENERALIZABILITY OF AD CLINICAL TRIALS BY RECRUITING UNDER-REPRESENTED GROUPS: THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI) |
|
|
|
|
| Donna |
Wilcock |
USA |
PLASMA BIOMARKER IDENTIFICATION FOR DEMENTIA-CAUSING PATHOLOGIES IN A LONGITUDINAL AGING COHORT WITH AUTOPSY |
| Bengt |
Winblad |
SWEDEN |
NEED FOR TREATMENT WITH SMALL, COST-EFFECTIVE MOLECULES IN ALZHEIMER DISEASE |
| Manfred |
Windisch |
Austria |
CAN PRE-CLINICAL MODEL SYSTEMS HELP US TO INCREASE THE RATE OF SUCCESS OF DRUG DEVELOPMENT FOR ALZHEIMER’S DISEASE AND RELATED NEURODEGENERATIVE DISORDERS? |
| Tony |
Wyss-Coray |
USA |
A MOLECULAR SYSTEMS APPROACH TO UNDERSTAND ALZHEIMER’S DISEASE |
| Huaxi |
Xu |
USA |
THE PATHOPHYSIOLOGICAL ROLE OF MICROGLIAL APOE |
| Henrik |
Zetterberg |
Sweden |
NOVEL CSF BIOMARKERS FOR SYNAPTIC AND LYSOSOMAL FUNCTION IN NEURODEGENERATIVE DISEASES |
| Berislav |
Zlokovic |
USA |
BLOOD-BRAIN BARRIER ROLE IN NEURODEGENERATION, COGNITIVE DYSFUNCTION AND ALZHEIMER’S DISEASE |